Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

th moderate to severe Crohn's disease to study the safety and efficacy of HUMIRA in maintaining clinical remission up to 56 weeks. After week four, 778 patients were randomized to placebo, HUMIRA 40 mg every other week (EOW) or 40 mg weekly (EW) in blinded fashion. At or after week 12, patients with flares or non-responders could receive open-label 40 mg EOW and 40 mg EW for continued flare or nonresponse.

The co-primary endpoints evaluated the maintenance of clinical remission at weeks 26 and 56 for each HUMIRA group compared to those on placebo. A significantly greater percentage of patients treated with HUMIRA maintained clinical remission at one year compared to placebo.

About the GAIN Trial

In the GAIN (Gauging Adalimumab effectiveness in Infliximab Nonresponders) study, a four-week induction trial of 325 patients who lost response or were intolerant to infliximab, three times as many patients taking HUMIRA achieved clinical remission at week four versus placebo (21 percent versus 7 percent, respectively).

"HUMIRA's ability to effectively treat the chronic symptoms of Crohn's disease makes it an important option for gastroenterologists and patients looking for improved disease management," said Eugene Sun, M.D., vice president, Global Pharmaceutical Clinical Development, Abbott.

HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy. HUMIRA is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

The recommended HUMIRA dose regimen for adult patients with Crohn's disease is 160 mg initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later (Day 15).
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MEMPHIS, Tenn. , May 29, 2015  Dr. ... his practice to resolve vaginal health issues often caused by ... painless and requires no anesthesia, received FDA clearance in 2014. ... Tennessee to offer the special fractional CO ... well as breast cancer survivors. In 2010 ...
(Date:5/29/2015)... LifeNet Health plans to enlarge its workforce ... more than 160 people. The organization,s growth ... innovative bio-implants, which are being made more widely available ... It also is a reflection of the region,s growing ... and success of LifeNet Health is a great example ...
(Date:5/29/2015)... and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... American Association of Cancer Research (AACR) Advances ... potential for its lead product candidate VAL-083 ...
Breaking Medicine Technology:The Newest FDA-Cleared Breakthrough In Women's Health Treatments 2LifeNet Health to add more than 160 jobs in 2015 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
... ( www.curemark.com ), a drug research and development company focused ... & Renshaw Annual Global Investment Conference held September 12-15 in ... 5,000 investors and other attendees.   "Curemark was ... present at the conference, which included a full roster of ...
... OmniComm Systems, Inc. (OTC Bulletin Board: ... and services announced that it will be hosting the ... Beach Resort in Fort Lauderdale, Florida from November 03-05, ... from participating Life Science organizations. The informal ambiance provides ...
Cached Medicine Technology:Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3
(Date:5/29/2015)... (PRWEB) May 29, 2015 Healthpointe is ... Joint Fluid Therapy (JFT) at their clinics in Orange ... injectable treatment that assists in diminishing pain for patients ... Dr. Stanley Katz and Dr. Neil Katz of Healthpointe. ... sodium hyaluronate (also known as hyaluronic acid) a natural ...
(Date:5/29/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 29, 2015 ... in the vulvar region and can cause significant physical, ... understands the major life altering disorder of Vulvodynia. The ... exclusion. At Women’s Excellence in Endometriosis, they realize that ... If a patient is experiencing any of these symptoms, ...
(Date:5/29/2015)... The popular all-natural supplement brand, Liporidex, ... Select Program that gives bonuses to members for their ... 100 members per year, lucky members who are selected ... fitness experts at Nuretix Research, and get exclusive benefits ... they attain and maintain their weight loss and fitness ...
(Date:5/29/2015)... Louisville, KY (PRWEB) May 29, 2015 ... private and government entities to discuss and foster the ... data to improve health. The Conference is hosted by ... government, non-profit, and private organizations to promote and develop ... conference, there are several focused groups to narrow in ...
(Date:5/29/2015)... External Counterpulsation, also known as EECP ... patients. The Heart Fit Clinic is the first clinic in ... review from patients who are now completing treatment. , ... treatments of ECP treatment and received great results. His ... does the clinic perform this non-surgical treatment for heart disease, ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 3Health News:External Counterpulsation at Heart Fit Clinic Receives Raving Review 2
... , , Web availability of ... CHARLESTON, S.C., Sept. 14 According to MUSC researchers, antibiotics ... despite efforts to control antibiotic-resistant bacteria as a result of misuse ... keyword search of "purchase antibiotics without a prescription" and "online" on ...
... , , , , ... A new critical illness plan from Colonial Life & Accident Insurance Company ... away from financial problems. Even with good health insurance, a serious illness, ... hook for huge expenses. , , "Even employees ...
... , , ROCKVILLE, Md., Sept. 14 ... Staying Active and Healthy with Blood Thinners , a new 10-minute ... to use anticoagulant drugs, commonly called blood thinners, safely. , ... thinners each year to reduce their risk of forming dangerous blood ...
... BOSTON, Sept. 14 Americans rate Alzheimer,s disease ... five million people living with this disease in the U.S. ... in the cause and prevention of Alzheimer,s disease, indicating that ... stave off this devastating illness. , , ...
... female patients , MONDAY, Sept. 14 (HealthDay News) -- ... with advanced heart failure. , A new analysis turns ... and then correct abnormal heart rhythms, actually lowered the ... that this is routine therapy for all patients with ...
... of other cancers, clots , MONDAY, Sept. 14 (HealthDay ... for developing breast cancer do reduce their cancer risk, ... analysis suggests. , That was the conclusion of researchers ... trials and a head-to-head assessment of the medications used ...
Cached Medicine News:Health News:MUSC Researchers Concerned About Online Drug Availability 2Health News:Critical Illness Plans Help Pay for What Health Insurance Won't 2Health News:Critical Illness Plans Help Pay for What Health Insurance Won't 3Health News:ahrq Announces New Video to Help Patients Use Blood Thinner Pills Safely and Effectively 2Health News:Senior Living Residences Launches Innovative Nutrition Program to Promote Cognitive Health and Lower the Risk of Alzheimer's Disease 2Health News:Implantable Defibrillators May Not Help Women With Heart Failure 2Health News:Implantable Defibrillators May Not Help Women With Heart Failure 3Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 2Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 3
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
... The SURPASS Perfusion Catheter is ... the stenotic portion of a ... stenosis for the purpose of ... Perfusion Catheters are also designed ...
Medicine Products: